Randomized, controlled trial of the clinical effect of selecrive SGLT2 blocker, ipragliflozin, and DPP-4 blocker in type 2 diabetic patients with NAFLD/NASH.- multicenter study -

Trial Profile

Randomized, controlled trial of the clinical effect of selecrive SGLT2 blocker, ipragliflozin, and DPP-4 blocker in type 2 diabetic patients with NAFLD/NASH.- multicenter study -

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 May 2017

At a glance

  • Drugs Alpha-glucosidase inhibitors (Primary) ; Ipragliflozin (Primary) ; Metformin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2017 Status changed from not yet recruiting to recruiting.
    • 10 Mar 2015 Planned number of patients changed from 20 to 128 as reported by University Hospital Medical Information Network - Japan.
    • 28 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top